Edition:
United Kingdom

People: Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

2.68USD
15 Aug 2018
Change (% chg)

$-0.08 (-2.72%)
Prev Close
$2.76
Open
$2.77
Day's High
$2.77
Day's Low
$2.66
Volume
75,979
Avg. Vol
740,288
52-wk High
$4.71
52-wk Low
$2.18

Ringrose, Peter 

Dr. Peter S. Ringrose, Ph.D., is Independent Director of Rigel Pharmaceuticals Inc., since February 2005. Dr. Ringrose's experience in the pharmaceutical industry spans more than 40 years and includes key leadership positions as Senior Vice President for Worldwide Drug Discovery and Medicinal R & D Europe at Pfizer Inc., a pharmaceutical company, and Division Director of Chemotherapy, Infectious Diseases and Molecular Sciences at the Sandoz Research Institute in Vienna, Austria. In 2002, Dr. Ringrose retired from Bristol-Myers Squibb, a pharmaceutical company, where he served as Chief Scientific Officer from January 2000 to December 2002, as well as President of the Pharmaceutical Research Institute from January 1997 to December 2002. Dr. Ringrose served as chair of the Biotechnology and Biological Sciences Research Council (UK) from 2003 until 2009, and was a member of the UK Government's Technology Strategy Board. He is a Council member of the Foundation for Science and Technology in the United Kingdom and also chairs the Corporate Partnership Board at Pembroke College, Cambridge where he is a lifetime Honorary Pitt Fellow. Dr. Ringrose served on the board of directors of Theravance, Inc Dr. Ringrose received a B.S., an M.A. and a Ph.D. from the University of Cambridge.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Raul Rodriguez

2,172,790

Dean Schorno

--

Dolly Vance

1,130,060

Anne-Marie Duliege

1,071,900

Eldon Mayer

712,036

Nelson Cabatuan

--
As Of  31 Dec 2017